What is Constructive Bio?
Constructive Bio is at the forefront of synthetic biology, pioneering novel methods for constructing entirely synthetic genomes and reprogramming the genetic code of living organisms. Their platform technologies are designed to create virus-resistant organisms and transform living cells into sustainable bio-factories. This capability is pivotal for realizing the future of sustainable materials and advanced therapies, positioning Constructive Bio as a key player in the burgeoning bio-economy.
How much funding has Constructive Bio raised?
Constructive Bio has raised a total of $73M across 2 funding rounds:
Angel/Seed
$15M
Series A
$58M
Angel/Seed (2022): $15M, investors not publicly disclosed
Series A (2024): $58M led by Paladin Capital Group, NanoDimension, Ahren Innovation Capital, Omx Ventures, and Fine Structure Ventures
Key Investors in Constructive Bio
Paladin Capital Group
Paladin Capital Group is a global multi-stage investment firm specializing in venture capital and growth financing. They strategically deploy capital to support companies from early-stage ventures through expansion phases, focusing on deep sector expertise and operational acumen to accelerate growth.
NanoDimension
ND Capital is a venture capital firm focused on investing in disruptive technologies across life, physical, and data sciences. They leverage their teams in the US and Europe to support portfolio companies in attracting capital and talent, seeking to build impactful companies.
Ahren Innovation Capital
Ahren Innovation Capital invests in transformational companies at the intersection of deep technology and deep science, partnering with founders from pre-seed to pre-IPO stages. Their focus areas include Brain & AI, Genetics & Platform Technologies, Space & Robotics, and Efficient Energy.
What's next for Constructive Bio?
The substantial enterprise-level funding and recent strategic investment signal a pivotal growth phase for Constructive Bio. This capital infusion is expected to accelerate the scaling of their platform technologies, enabling broader applications in sustainable materials and therapeutic development. Constructive Bio is likely to focus on expanding its research and development capabilities, forging strategic partnerships, and potentially moving towards commercialization of its bio-factories. The company's trajectory suggests a move from early-stage development towards significant market penetration, leveraging its unique genetic engineering capabilities to address global challenges in sustainability and healthcare.
See full Constructive Bio company page
